lobbying_activities: 3189611

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
3189611	e0918c5c-b2da-400e-878b-15b8bec85069	Q2	PUBLIC CITIZEN	32362	PUBLIC CITIZEN	2024	second_quarter	PHA	Medicare drug price negotiation eligibility, providing negotiated prices to commercial market and other improvements, Medicare Part D noninterference clause, clinical trial cost transparency, march-in rights and other Bayh-Dole rights, PASTEUR Act, Plain Prescription Prices Act, public pharmaceutical manufacturing, .79 Interagency Patent Coordination and Improvement Act; S.113 Prescription Pricing for the People Act; S.142 Preserve Access to Affordable Generics and Biosimilars Act; S.148 Stop STALLING Act; S.150, S.954 Affordable Insulin Now Act, weight loss drug pricing.	Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office		73300	0	0	2024-07-12T14:06:41-04:00